Open AccessUse of NOACs Versus Vitamin K Antagonist in Atrial Fibrillation Catheter Ablation: An Updated Meta-analysis With Subgroup Analysis
Author(s) -
Sukhdeep Bhogal,
Kajal Mawa,
Tarun Bhandari,
Vijay Ramu
Publication year - 2021
Publication title -
american journal of therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.349
H-Index - 62
eISSN - 1536-3686
pISSN - 1075-2765
DOI - 10.1097/mjt.0000000000001391
Subject(s) - medicine , dabigatran , rivaroxaban , apixaban , atrial fibrillation , vitamin k antagonist , mace , subgroup analysis , catheter ablation , randomized controlled trial , odds ratio , warfarin , confidence interval , cardiology , anesthesia , percutaneous coronary intervention , myocardial infarction
Current guidelines give class I recommendations for uninterrupted use of dabigatran rivaroxaban as an alternative to vitamin K antagonist (VKA) in patients of atrial fibrillation (AF) who are undergoing catheter ablation. The recent randomized controlled trials have shown similar efficacy of novel oral anticoagulants when compared to VKA in these patients. We sought to perform a meta-analysis with a focus on subgroup analysis of novel oral anticoagulants.